Ranexa Restricted Angina Indication Would Require New Study, Cmte. Says
Executive Summary
CV Therapeutics' Ranexa could receive a restricted indication for use in refractory angina patients with a new study in that population, FDA's Cardiovascular & Renal Drugs Advisory Committee said Dec. 9